More News! 14 Sep 2017 New Dutch Spin Out will Treat Stroke with RNA Therapy ProQR has spun out Amylon Therapeutics, a company that will treat central nervous system disorders with a lead candidate based on RNA technology. Amylon Therapeutics, a brand new spin-out from RNA company ProQR, has announced its first seed investment round. The funds, of an undisclosed amount, will help the new company kick off the development of its drug candidates. Based in Leiden, Amylon […] September 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 14 Sep 2017 Inside the Lab Building a Stem Cell Gun to Heal Skin Thomas Bold, CEO of RenovaCare, shares the story of how his team developed a futuristic stem cell gun to heal burns and wounds. Inside the building that used to be home to Berlin’s Tempelhof airport, whose abandoned runways are regularly visited by picnickers and skaters, an American and a German company are collaborating on the […] September 14, 2017 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2017 A Swedish-Spanish Team Takes on a New Immuno-Oncology Target Alligator Bioscience will collaborate with the University of Navarra, Spain, to study the potential of CD137 as a target for new cancer immunotherapies. Alligator Bioscience, based in Lund, Sweden, has teamed up with Prof. Ignacio Melero at the Center for Applied Medical Research (CIMA) at the University of Navarra to study the biological effects of activating […] September 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2017 Epigenetics Drug Proves Effective in Phase I for Lethal Cancer 4SC’s partner Yakult Honsha has presented positive results at ESMO 2017 for the epigenetics drug resminostat in a Phase I trial run in Japan. The histone deacetylase (HDAC) inhibitor resminostat has shown to induce tumor shrinkage or disease stabilization in all patients with biliary tract cancer in a Phase I trial. The goal was to determine […] September 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2017 Series D Boost will Bring Artificial Intelligence to Diagnostics Worldwide Sophia Genetics has raised $30M (€25M) in Series D that will be directed to growing and improving its artificial intelligence platform for genetic diagnostics. The Swiss company Sophia Genetics has announced today a new round of funding, led by Balderton Capital, and joined by 360º Capital Partners and existing investors Invoke Capital and Alychlo. The […] September 13, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Infographics 13 Sep 2017 The 10 Most Innovative HIV Treatments to Defeat AIDS This infographic gathers 10 of the best HIV treatments in Europe’s pipeline that will help doctors worldwide fight against AIDS better than ever before. With an estimated 36.7 million people living with HIV worldwide, the search for an effective treatment that can overcome the fast evolution of the virus is rapidly gaining traction. In Europe, […] September 13, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2017 France Invests €15M in Developing a New Generation of Antibiotics Deinove has received funding from Bpifrance to work on the discovery of the next generation of antibiotics to fight antibiotic-resistant pathogens. The Investments for the Future Program, operated by the French public investment bank Bpifrance, has granted €14.6M to the Antibiotics against Resistant Infectious Germs (AGIR) project, carried out by the Deinove group in collaboration […] September 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2017 French Nanoparticle Therapy Fails to Improve Liver Cancer Treatment in Phase III Onxeo has announced Phase III results for its nanoparticle chemotherapy Livatag, which failed to improve the outcome for patients with hepatocellular carcinoma compared to other available treatments. The stock of the French oncology specialist Onxeo was halved this morning when it revealed the results of a Phase III trial with its candidate Livatag that failed to […] September 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2017 French Startup Raises €11M in Series A to Reinvent DNA Synthesis DNA Script has gathered the support of key international investors to take a new, faster DNA synthesis technology closer to the market. In a Series A round led by Illumina Ventures and joined by Merck Ventures and existing investors Sofinnova Partners, Kurma Partners, and Idinvest Partners, the young French startup DNA Script has raised a total […] September 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 Sep 2017 Gecko Biomedical’s Bio-inspired Surgical Glue Gets EU Approval Gecko Biomedical has received CE Mark for Setalum, a light-activated biocompatible sealant, for its use in vascular reconstruction surgery. The Parisian company Gecko Biomedical has received today marketing approval in Europe for its first product; Setalum is a biocompatible polymer that can be activated on demand with light to give surgeons more control during open […] September 11, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Sep 2017 The Music of the Microbiome Questions our Identity as Humans Slovenian artists Saša Spačal, Mirjan Švagelj and Anil Podgornik explore the meaning of human identity by letting their microbiome play music. Have you ever wondered what the microbes that live in and on you would tell you if you listened to them? A group of Slovenian artists decided to let their own microbes make music, building […] September 9, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2017 Checkpoint Inhibitor from Regeneron and Sanofi gets Priority After Breakup The FDA has granted breakthrough therapy designation to Regeneron and Sanofi for cemiplimab, just a month after announcing they will part ways soon. Cemiplimab (REGN2810) has been granted breakthrough therapy designation by the FDA for the treatment of metastatic cutaneous squamous cell carcinoma (CSCC), considered the second deadliest skin cancer after melanoma. The antibody is a […] September 8, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email